
A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

Check out some of the top clinical pearls gleaned from presenters at Real Psychiatry.

Check out 2 high-level examples of patient quality of life improvement following treatment for tardive dyskinesia.

What are the signs of increased struggle with tardive dyskinesia? Here's what Erin Crown, MHS, PA-C, Psych-CAQ, picks up on during patient visits.

Tardive dyskinesia can be difficult to discern...

Here's how to address medication side effects with patients.

COVID-19 increased the usage of telemedicine drastically, but is that always a good thing?

What 5 factors should you look at when selecting ADHD treatment?

Let's explore COVID-19's impact on psychiatric research...

"Who are you important to? If you passed tomorrow, who would show up at your funeral?"

When a patient has comorbidities like anxiety, substance use, and depression, how can you best select a treatment?

Come celebrate the evolution of Psychiatric Times and psychiatry as a whole!

When prescribing ADHD medications, when is the best time to switch treatments?

How can we improve patient outcomes? Collaboration.

Ancillary symptoms may be key in guiding treatment management for ADHD.

Here are 4 things to do when implementing a treatment strategy for tardive dyskinesia.

Comorbid bipolar disorder and ADHD: a big problem.

Here's how to have productive conversations with patients with tardive dyskinesia in order to improve outcomes.

How can we get back to recovery as the treatment goal for schizophrenia?

2024 into 2025: a period of highs and lows for schizophrenia treatment.

We're excited to preview our new upcoming partnership with the Psych NP Network at Real Psychiatry!

How has bipolar treatment changed over the past 40 years? The celebration of 40 years of Psychiatric Times continues at the Real Psychiatry conference.

Check out these top tips for treating postpartum depression from the Real Psychiatry conference!

The top 3 issues in treating bipolar disorder are...

Digital therapeutics may help improve negative symptoms associated with schizophrenia.

We've upgraded our phones and computers... is it time to upgrade our psychiatric medications?

Carmen Kosicek, MSN, PMHNP-BC, is ready to teach nurse practitioners and advanced providers in a fun, innovative way at Real Psychiatry in Scottsdale, AZ.

Are you attending Real Psychiatry this weekend?